Enovis [ENOV] vs Procept BioRobotics [PRCT] Detailed Stock Comparison
Enovis
NYSE
Loading...
Procept BioRobotics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Enovis wins in 10 metrics, Procept BioRobotics wins in 8 metrics, with 0 ties. Enovis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Enovis | Procept BioRobotics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -2.04 | -19.85 | Procept BioRobotics |
| Price-to-Book Ratio | 0.67 | 5.14 | Enovis |
| Debt-to-Equity Ratio | 56.75 | 20.57 | Procept BioRobotics |
| PEG Ratio | -0.02 | 0.66 | Enovis |
| EV/EBITDA | 8.68 | -20.51 | Procept BioRobotics |
| Profit Margin (TTM) | -37.80% | -30.60% | Procept BioRobotics |
| Operating Margin (TTM) | 2.41% | -28.02% | Enovis |
| EBITDA Margin (TTM) | 2.41% | N/A | N/A |
| Return on Equity | -28.25% | -26.40% | Procept BioRobotics |
| Return on Assets (TTM) | 0.89% | -12.93% | Enovis |
| Free Cash Flow (TTM) | $-67.21M | $-103.62M | Enovis |
| Dividend Yield | N/A | 0.64% | N/A |
| 1-Year Return | -24.92% | -52.11% | Enovis |
| Price-to-Sales Ratio (TTM) | 0.79 | 7.42 | Enovis |
| Enterprise Value | $3.15B | $1.76B | Enovis |
| EV/Revenue Ratio | 1.44 | 6.41 | Enovis |
| Gross Profit Margin (TTM) | 59.29% | 65.35% | Procept BioRobotics |
| Revenue per Share (TTM) | $39 | $5 | Enovis |
| Earnings per Share (Diluted) | $-15.04 | $-1.50 | Procept BioRobotics |
| Beta (Stock Volatility) | 1.79 | 1.03 | Procept BioRobotics |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Enovis vs Procept BioRobotics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Enovis | 0.30% | 1.77% | -0.94% | -8.70% | -17.39% | -31.04% |
| Procept BioRobotics | 0.20% | -6.00% | -12.05% | -40.19% | -39.73% | -58.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Enovis | -24.92% | -33.49% | -44.86% | -42.67% | 13.99% | -13.41% |
| Procept BioRobotics | -52.11% | -13.09% | -13.00% | -13.00% | -13.00% | -13.00% |
News Based Sentiment: Enovis vs Procept BioRobotics
Enovis
News based Sentiment: POSITIVE
October was a notably positive month for Enovis, marked by significant analyst upgrades, substantial insider buying activity, and a clear strategic direction under its new CEO. These developments suggest growing confidence in the company's future prospects and potential for growth, making it a significant month for investors.
Procept BioRobotics
News based Sentiment: MIXED
September presented a mixed bag for Procept BioRobotics, with strong Q2 earnings and positive analyst ratings countered by stock volatility, insider selling, and downward price target revisions. The conflicting signals create a complex investment picture, making it a significant month for the company's trajectory.
Performance & Financial Health Analysis: Enovis vs Procept BioRobotics
| Metric | ENOV | PRCT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.74B | $1.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 830,007 | 902,800 |
| 90 Day Avg. Volume | 931,692 | 951,347 |
| Last Close | $30.55 | $34.80 |
| 52 Week Range | $25.47 - $49.83 | $34.01 - $103.81 |
| % from 52W High | -38.69% | -66.48% |
| All-Time High | $129.72 (Jun 09, 2014) | $103.81 (Nov 11, 2024) |
| % from All-Time High | -76.45% | -66.48% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.48% |
| Quarterly Earnings Growth | 0.08% | 0.48% |
| Financial Health | ||
| Profit Margin (TTM) | -0.38% | -0.31% |
| Operating Margin (TTM) | 0.02% | -0.28% |
| Return on Equity (TTM) | -0.28% | -0.26% |
| Debt to Equity (MRQ) | 56.75 | 20.57 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $45.11 | $6.94 |
| Cash per Share (MRQ) | $0.77 | $5.44 |
| Operating Cash Flow (TTM) | $188.06M | $-83,214,000 |
| Levered Free Cash Flow (TTM) | $65.68M | $-59,140,124 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.64% |
| Last 12-Month Dividend | $0.00 | $0.38 |
Valuation & Enterprise Metrics Analysis: Enovis vs Procept BioRobotics
| Metric | ENOV | PRCT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -2.04 | -19.85 |
| Forward P/E | 9.60 | -26.83 |
| PEG Ratio | -0.02 | 0.66 |
| Price to Sales (TTM) | 0.79 | 7.42 |
| Price to Book (MRQ) | 0.67 | 5.14 |
| Market Capitalization | ||
| Market Capitalization | $1.74B | $1.99B |
| Enterprise Value | $3.15B | $1.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.44 | 6.41 |
| Enterprise to EBITDA | 8.68 | -20.51 |
| Risk & Other Metrics | ||
| Beta | 1.79 | 1.03 |
| Book Value per Share (MRQ) | $45.11 | $6.94 |
Financial Statements Comparison: Enovis vs Procept BioRobotics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ENOV | PRCT |
|---|---|---|
| Revenue/Sales | $564.55M | $69.16M |
| Cost of Goods Sold | $229.85M | $25.00M |
| Gross Profit | $334.70M | $44.16M |
| Research & Development | $30.70M | $16.40M |
| Operating Income (EBIT) | $-16.08M | $-27.44M |
| EBITDA | $55.91M | $-22.39M |
| Pre-Tax Income | $-25.65M | $-24.74M |
| Income Tax | $10.80M | N/A |
| Net Income (Profit) | $-36.55M | $-24.74M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ENOV | PRCT |
|---|---|---|
| Cash & Equivalents | $38.46M | $316.21M |
| Total Current Assets | $1.22B | $465.79M |
| Total Current Liabilities | $477.42M | $52.06M |
| Long-Term Debt | $1.42B | $77.83M |
| Total Shareholders Equity | $2.62B | $389.16M |
| Retained Earnings | $-338.99M | $-570.72M |
| Property, Plant & Equipment | $492.24M | $21.26M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ENOV | PRCT |
|---|---|---|
| Operating Cash Flow | $-1.07M | $-11.65M |
| Capital Expenditures | $-43.26M | $-1.84M |
| Free Cash Flow | $-44.86M | $-18.82M |
| Debt Repayment | $-15.44M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ENOV | PRCT |
|---|---|---|
| Shares Short | 6.93M | 8.15M |
| Short Ratio | 7.31 | 8.52 |
| Short % of Float | 0.18% | 0.17% |
| Average Daily Volume (10 Day) | 830,007 | 902,800 |
| Average Daily Volume (90 Day) | 931,692 | 951,347 |
| Shares Outstanding | 55.88M | 54.72M |
| Float Shares | 56.42M | 53.56M |
| % Held by Insiders | 0.02% | 0.05% |
| % Held by Institutions | 1.21% | 0.98% |
Dividend Analysis & Yield Comparison: Enovis vs Procept BioRobotics
| Metric | ENOV | PRCT |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $0.38 |
| Last 12-Month Dividend Yield | N/A | 0.64% |
| 3-Year Avg Annual Dividend | $0.00 | $0.53 |
| 3-Year Avg Dividend Yield | N/A | 0.12% |
| 3-Year Total Dividends | $0.00 | $1.59 |
| Ex-Dividend Date | N/A | Mar 31, 2025 |